Century Therapeutics (IPSC) Net Equity Issued and Repurchased (2021 - 2026)
Century Therapeutics (IPSC) posted quarterly Net Equity Issued and Repurchased of $202000.0 for Q1 2026, up 68.33% year-over-year from $120000.0 in Q1 2025, and up 281.13% quarter-over-quarter from $53000.0 in Q4 2025.
Powered by 
Analysis
Century Therapeutics (IPSC) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Net Equity Issued and Repurchased for 6 consecutive years, with $202000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased rose 68.33% year-over-year to $202000.0; the TTM figure through Mar 2026 stood at $255000.0 (up 342.86% YoY), while the FY2025 annual figure was $173000.0, up 22.7% from the prior year.
- Net Equity Issued and Repurchased improved to $202000.0 in Q1 2026 per IPSC's latest filing, from $53000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $448000.0 in Q1 2023 and bottomed at -$602000.0 in Q4 2024.
- Historically, Net Equity Issued and Repurchased has averaged $91800.0 across 5 years, with a median of $120000.0 in 2025.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 589.23% in 2023 and fell as far as 474.74% in 2023.
- Century Therapeutics' Net Equity Issued and Repurchased stood at $95000.0 in 2022, then slumped by 474.74% to -$356000.0 in 2023, then sank by 69.1% to -$602000.0 in 2024, then soared by 108.8% to $53000.0 in 2025, then surged by 281.13% to $202000.0 in 2026.
- Business Quant data shows IPSC's Net Equity Issued and Repurchased at $202000.0 in Q1 2026, $53000.0 in Q4 2025, and $120000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Century Therapeutics | 440.37 Mn | 180.29 Mn | - | 347,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 347,000.00 |
| Mar 31, 2026 | 202,000.00 |
| Dec 31, 2025 | 53,000.00 |
| Mar 31, 2025 | 120,000.00 |
| Dec 31, 2024 | -602,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | 104,000.00 |
| Mar 31, 2024 | 366,000.00 |
| Dec 31, 2023 | -356,000.00 |
| Sep 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 124,000.00 |
| Mar 31, 2023 | 448,000.00 |
| Dec 31, 2022 | 95,000.00 |
| Sep 30, 2022 | 137,000.00 |
| Jun 30, 2022 | 48,000.00 |
| Mar 31, 2022 | 65,000.00 |
| Mar 31, 2021 | 159.63 Mn |